Stockscreener 앱 받기
1.88
5.03%
0.09
시간 외 거래:
1.85
-0.03
-1.60%
전일 마감가:
$1.79
열려 있는:
$1.77
하루 거래량:
1.90M
Relative Volume:
1.38
시가총액:
$42.64M
수익:
$151.12M
순이익/손실:
$-194.97M
주가수익비율:
-0.1246
EPS:
-15.0871
순현금흐름:
$-59.11M
1주 성능:
+16.77%
1개월 성능:
-2.59%
6개월 성능:
-77.62%
1년 성능:
-67.19%
1일 변동 폭
$1.6701
$1.885
1주일 범위
$1.525
$1.885
52주 변동 폭
$1.24
$10.99
Karyopharm Therapeutics Inc Stock (KPTI) Company Profile
명칭
Karyopharm Therapeutics Inc
전화
617-658-0600
주소
85 WELLS AVENUE, NEWTON, MA
Compare KPTI vs VRTX, REGN, ARGX, MRNA, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
KPTI
Karyopharm Therapeutics Inc
|
1.88 | 36.52M | 151.12M | -194.97M | -59.11M | -15.09 |
VRTX
Vertex Pharmaceuticals Inc
|
508.34 | 130.64B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
784.85 | 80.46B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
990.32 | 61.58B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
154.04 | 57.48B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
190.95 | 43.68B | 742.00K | -1.37B | -1.07B | -7.0731 |
Karyopharm Therapeutics Inc Stock (KPTI) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-03-10 | 개시 | Rodman & Renshaw | Buy |
| 2026-02-05 | 개시 | Cantor Fitzgerald | Overweight |
| 2025-10-13 | 업그레이드 | H.C. Wainwright | Neutral → Buy |
| 2025-07-16 | 다운그레이드 | H.C. Wainwright | Buy → Neutral |
| 2025-07-11 | 재개 | H.C. Wainwright | Buy |
| 2023-01-19 | 개시 | Piper Sandler | Overweight |
| 2022-11-04 | 업그레이드 | RBC Capital Mkts | Sector Perform → Outperform |
| 2022-02-09 | 업그레이드 | JP Morgan | Underweight → Neutral |
| 2021-11-19 | 재개 | Morgan Stanley | Equal-Weight |
| 2021-08-06 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2021-08-06 | 다운그레이드 | RBC Capital Mkts | Outperform → Sector Perform |
| 2021-08-06 | 다운그레이드 | SVB Leerink | Outperform → Mkt Perform |
| 2020-07-02 | 개시 | Morgan Stanley | Overweight |
| 2020-03-04 | 개시 | Barclays | Overweight |
| 2020-01-17 | 다운그레이드 | Wedbush | Outperform → Neutral |
| 2019-07-23 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2019-07-05 | 재확인 | H.C. Wainwright | Buy |
| 2019-07-05 | 재확인 | Robert W. Baird | Outperform |
| 2019-03-01 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2019-02-28 | 재확인 | BofA/Merrill | Underperform |
| 2019-02-27 | 다운그레이드 | BofA/Merrill | Neutral → Underperform |
| 2019-01-03 | 업그레이드 | BofA/Merrill | Underperform → Neutral |
| 2018-12-03 | 개시 | B. Riley FBR | Buy |
| 2018-11-09 | 업그레이드 | Wedbush | Neutral → Outperform |
| 2018-05-24 | 다운그레이드 | Wedbush | Outperform → Neutral |
| 2018-04-02 | 재개 | Leerink Partners | Outperform |
| 2017-11-15 | 재개 | H.C. Wainwright | Buy |
| 2017-09-15 | 개시 | RBC Capital Mkts | Outperform |
| 2016-09-08 | 재확인 | H.C. Wainwright | Buy |
| 2016-08-30 | 업그레이드 | Jefferies | Hold → Buy |
| 2016-08-18 | 개시 | H.C. Wainwright | Buy |
| 2016-06-28 | 개시 | Robert W. Baird | Outperform |
모두보기
Karyopharm Therapeutics Inc 주식(KPTI)의 최신 뉴스
KPTI Slides As Legal, Cash Pressures Rattle Traders - StocksToTrade
Form 8K Karyopharm Therapeutics Inc For: 11 September By Investing.com - Investing.com South Africa
Karyopharm Skips $15.8 Million Debt Payment, Warns of Going-Concern Risk - Minichart
KPTI Looks 64.4% Undervalued on GF Value™ but Faces Significant Financial Struggles - GuruFocus
Karyopharm TherapeuticsEnters Forbearance Agreement And Waiver On Sept 10, 2026SEC Filing - TradingView
Karyopharm Wins Forbearance to Oct. 15, Will Issue $20M 0% Convertible Preferred - TradingView
Karyopharm pushes off debt payment; Amgen eyes broader Imdelltra use - Yahoo Finance
SpaceX Stock Price Today | SPCX Ticker, News, Retail Sentiment - Stocktwits
Karyopharm Therapeutics Inc (NASDAQ: KPTI) Share Price, KPTI Stock News, KPTI Share Price & Updates - Kalkine
Why Is KPTI Stock Down 69% After-Hours Today? - Stocktwits
Karyopharm Therapeutics Stock Price Forecast. Should You Buy KPTI? - StockInvest.us
Israel Englander group discloses new Karyopharm stake (NASDAQ: KPTI) - Stock Titan
Karyopharm Therapeutics (KPTI) Stock Fair Value Falls After Split Analyst Views On Trial Updates - Yahoo Finance
Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) - TradingView
Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Karyopharm
Karyopharm Seeks FDA Approval for XPOVIO Plus Ruxolitinib in Myelofibrosis - Cure Today
A Second Drug for a Disease That Has Only Ever Had One: Karyopharm Files for Selinexor Plus Ruxolitinib in Myelofibrosis - Onco'Zine
Karyopharm Therapeutics Submits Supplemental New Drug Application to the Fda for Xpovio Plus Ruxolitinib for Patients with Myelofibrosis - marketscreener.com
Karyopharm Therapeutics submits sNDA seeking accelerated approval for selinexor plus ruxolitinib in myelofibrosis - TradingView
KPTI Looks 60.5% Undervalued on GF Value™ Amid Challenging Funda - GuruFocus
Karyopharm Submits Supplemental New Drug Application to the FDA for XPOVIO® (selinexor) Plus Ruxolitinib for Patients with Myelofibrosis - Karyopharm
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Karyopharm Therapeutics Inc.KPTI - FinancialContent
Karyopharm’s (KPTI) Big Cancer Bet Faces A Ticking Clock - Yahoo Finance
Conferencia de resultados del 2T de 2026 de Karyopharm (KPTI): foco en la sNDA de selinexor y la liquidez - TradingKey
Karyopharm (KPTI) Q2 2026 Earnings Call Transcript - AOL.com
KPTI Stock Price and Chart — NASDAQ:KPTI - TradingView
Earnings Release: Here's Why Analysts Cut Their Karyopharm Therapeutics Inc. (NASDAQ:KPTI) Price Target To US$6.40 - simplywall.st
RA Capital boosts Karyopharm (KPTI) stake to 9.99% beneficial ownership cap - Stock Titan
Karyopharm Therapeutics (KPTI): Commodore Capital now reports 0.0% ownership - Stock Titan
KPTI|Karyopharm Therapeutics Inc|Price:2.015|Chg%:+0.025 - TradingKey
Karyopharm Therapeutics Inc. Q2 2026 Earnings Call Summary - Yahoo Finance
Karyopharm (KPTI) Ergebniskonferenz Q2 2026: Fokus auf Selinexor-sNDA und Liquidität - TradingKey
Karyopharm Therapeutics Inc (KPTI) Earnings, Actual EPS, EPS Estimates & Results - Stocktwits
Karyopharm Therapeutics Inc (KPTI) (Q2 2026) Earnings Call Highlights: SENTRY Trial Success and ... - Yahoo! Finance Canada
Karyopharm Therapeutics Inc (KPTI) (Q2 2026) Earnings Call Highl - GuruFocus
It's crunch time for Karyopharm as company faces potential default next month - Fierce Pharma
Karyopharm Therapeutics has cash to last only into next month - The Business Journals
Karyopharm Therapeutics Releases Q2 2026 Financial Results - AlphaStreet
Karyopharm Q2 2026 slides: myelofibrosis sNDA planned for August By Investing.com - Investing.com Australia
Karyopharm Therapeutics Q2 2026 Earnings Call Transcript - marketbeat.com
Karyopharm Q2 2026 slides: myelofibrosis sNDA planned for August - Investing.com
Karyopharm Q2 2026 slides: myelofibrosis data shines amid cash crunch - Investing.com
Karyopharm Therapeutics Inc. reports results for the quarter ended June 30Earnings Summary - TradingView
KPTI: Selinexor sNDA for myelofibrosis advances amid strong data, stable sales, and liquidity focus - TradingView
Earnings call transcript: Karyopharm Q2 2026 loss widens as cash pressure mounts - Investing.com
Karyopharm Therapeutics Inc. 2026 Q2ResultsEarnings Call Presentation (NASDAQ:KPTI) 2026-08-13 - Seeking Alpha
Form 8K Karyopharm Therapeutics Inc For: 13 August By Investing.com - Investing.com Nigeria
Karyopharm Therapeutics Reports Q2 2026 Results: Full Earnings Call Transcript - Benzinga
Karyopharm Therapeutics (KPTI) Reports Q2 Loss, Beats Revenue Estimates - Yahoo Finance
Karyopharm Therapeutics Inc. Reaffirms Earnings Guidance for the Full-Year of 2026 - marketscreener.com
Is Karyopharm Therapeutics Inc (KPTI) Undervalued at 64.1%? Q2 E - GuruFocus
Karyopharm Therapeutics Inc (KPTI) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Karyopharm Therapeutics Inc 주식 (KPTI) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Poulton Stuart | EVP, Chief Development Officer |
Jul 28 '26 |
Sale |
7.10 |
189 |
1,342 |
94,632 |
| Poulton Stuart | EVP, Chief Development Officer |
May 14 '26 |
Sale |
9.50 |
403 |
3,828 |
94,821 |
| Rangwala Reshma | EVP & Chief Medical Officer |
May 14 '26 |
Sale |
9.50 |
408 |
3,876 |
56,829 |
| Cheng Sohanya Roshan | EVP & Chief Commercial Officer |
May 14 '26 |
Sale |
9.50 |
324 |
3,078 |
107,940 |
| Abate Kristin | Chief Accounting Officer |
May 14 '26 |
Sale |
9.50 |
53 |
504 |
23,801 |
| Paulson Richard A. | President and CEO |
May 14 '26 |
Sale |
9.50 |
2,203 |
20,928 |
269,747 |
| Mano Michael | EVP, CLO&Secretary |
May 14 '26 |
Sale |
9.50 |
266 |
2,527 |
94,398 |
| Rangwala Reshma | EVP & Chief Medical Officer |
Apr 21 '26 |
Sale |
8.94 |
449 |
4,014 |
56,290 |
| Mano Michael | EVP, CLO&Secretary |
Mar 02 '26 |
Sale |
9.41 |
3,526 |
33,178 |
93,964 |
| Rangwala Reshma | EVP & Chief Medical Officer |
Mar 02 '26 |
Sale |
9.41 |
5,066 |
47,669 |
56,739 |
0.88%
자본화:
|
볼륨(24시간):